Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Free Cash Flow: 2015-2025

Historic Free Cash Flow for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$76.9 million.

  • Intellia Therapeutics' Free Cash Flow rose 10.67% to -$76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$412.6 million, marking a year-over-year decrease of 13.65%. This contributed to the annual value of -$354.7 million for FY2024, which is 13.09% up from last year.
  • Intellia Therapeutics' Free Cash Flow amounted to -$76.9 million in Q3 2025, which was up 22.96% from -$99.9 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Free Cash Flow high stood at -$54.8 million for Q1 2021, and its period low was -$149.7 million during Q1 2025.
  • Its 3-year average for Free Cash Flow is -$99.0 million, with a median of -$94.6 million in 2023.
  • In the last 5 years, Intellia Therapeutics' Free Cash Flow tumbled by 199.18% in 2021 and then skyrocketed by 37.44% in 2024.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Free Cash Flow stood at -$57.5 million in 2021, then plummeted by 63.04% to -$93.8 million in 2022, then decreased by 0.85% to -$94.6 million in 2023, then grew by 8.88% to -$86.2 million in 2024, then grew by 10.67% to -$76.9 million in 2025.
  • Its last three reported values are -$76.9 million in Q3 2025, -$99.9 million for Q2 2025, and -$149.7 million during Q1 2025.